Special Issues

Special Issue Title: COVID‐19 Pandemic Impact on Gynaecological Cancers

· Print Special Issue Flyer

· Deadline for manuscript submissions: 31 May 2022

Special Issue Editor

Guest Editor

Dr. Giuseppe Carlo Iorio, MD

Department of Oncology, Radiation Oncology, University of Turin, Turin, Italy

Website | E-Mail

Interests: Radiation Oncology; Radiobiology; Pelvic Malignancies; Head & Neck Cancer; GI cancer; Lymphomas; Breast Cancer

Special Issue Information

Dear Colleagues,

Coronavirus Disease 2019 (COVID-19) at the end of May 2021 has surpassed 167,000,000 cases and 3,400,000 deaths worldwide due to a severe acute respiratory syndrome (SARS-CoV-2), leading to heavy stress for the healthcare system.
Cancer patients are more susceptible to develop an infection than people without cancer because of their immunosuppression caused by the disease and treatments (surgery, radiotherapy, and chemotherapy). Indeed, chemo- and radiotherapy-related hematologic toxicity, particularly leukopenia and lymphopenia, play a pivotal role in this immunosuppressed state. Therefore, these patients are at higher risk of infection with COVID-19 and a much higher risk of developing more severe forms. Nonetheless, lymphopenia has also proved to affect the oncological prognosis of cancer patients, and thus its importance has been remarked during the present Pandemic. Given this epidemiological context, guidelines for patients with Gynaecological Cancers requiring multidisciplinary management during the COVID-19 Pandemic have represented a crucial step in limiting their infection while maintaining their chances for a cure. 
Therefore, in the present Special Issue, we aim to present evidence on the management of Gynaecological malignancies (and Breast Cancer) during the COVID-19 Pandemic and on the critical role of treatment-tailoring to avoid hematologic toxicity given its implications during and beyond the Pandemic.

Dr. Giuseppe Carlo Iorio

Guest Editor


Manuscript Submission Information

Manuscripts should be submitted online at https://ejgo.imrpress.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1250. Submitted papers should be well formatted and use good English.


Gynaecological Cancers; COVID-19 Pandemic; Ovarian Cancer; Endometrial Cancer; Cervical Cancer; Breast Cancer; Radiotherapy; Chemotherapy; Surgery; Toxicity

Share This Special Issue


Please wait a minute...
For Selected: Toggle Thumbnails

Current Issue

  • Volume 42, Issue 5